Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant, BA.
2.86, has emerged and spread to numerous countries worldwide, raising alarm because its …

Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …

Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals
previously infected with SARS-CoV-2, but the relative contributions of these different …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more
than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 …

The COVID-19 pandemic caused by the SARS-CoV-2 virus has led to more than 270 million
infections and 5.3 million of deaths worldwide. Several major variants of SARS-CoV-2 have …

Neutralizing antibodies (nAbs) elicited against the receptor binding site (RBS) of the spike
protein of wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are …